Do analysts prefer SKYE or APVO?

Skye Bioscience presently has a consensus price target of $8.50, indicating a potential upside of 1,491.76%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Skye Bioscience is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has stronger valuation & earnings, SKYE or APVO?

Skye Bioscience is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A

Is SKYE or APVO more profitable?

Aptevo Therapeutics' return on equity of -198.50% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% Aptevo Therapeutics N/A -198.50% -117.06%

Does the media prefer SKYE or APVO?

In the previous week, Skye Bioscience had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Skye Bioscience and 1 mentions for Aptevo Therapeutics. Skye Bioscience's average media sentiment score of 0.37 beat Aptevo Therapeutics' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aptevo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ALLR or APVO?

Allarity Therapeutics currently has a consensus target price of $10.25, suggesting a potential upside of 630.06%. Given Allarity Therapeutics' higher probable upside, equities research analysts plainly believe Allarity Therapeutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is ALLR or APVO more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Aptevo Therapeutics N/A -198.50% -117.06%

Do analysts prefer MRKR or APVO?

Marker Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 788.89%. Given Marker Therapeutics' higher probable upside, research analysts plainly believe Marker Therapeutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Do analysts rate NCEL or APVO?

NLS Pharmaceutics currently has a consensus target price of $23.00, indicating a potential upside of 621.00%. Given NLS Pharmaceutics' higher probable upside, research analysts clearly believe NLS Pharmaceutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has preferable valuation and earnings, NCEL or APVO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A

Is NCEL or APVO more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Aptevo Therapeutics N/A -198.50% -117.06%

Do analysts prefer QNTM or APVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has preferable earnings & valuation, QNTM or APVO?

Quantum Biopharma is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A

Is QNTM or APVO more profitable?

Aptevo Therapeutics' return on equity of -198.50% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -941.54% -224.41% Aptevo Therapeutics N/A -198.50% -117.06%

Does the media prefer QNTM or APVO?

In the previous week, Quantum Biopharma had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Quantum Biopharma and 1 mentions for Aptevo Therapeutics. Quantum Biopharma's average media sentiment score of 1.05 beat Aptevo Therapeutics' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aptevo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aptevo Therapeutics (APVO) Competitors

$4.12 -0.06 (-1.44%)

As of 12:24 PM Eastern

Compare

APVO vs. SKYE, ALLR, MRKR, NCEL, and QNTM

Should you buy Aptevo Therapeutics stock or one of its competitors? MarketBeat compares Aptevo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptevo Therapeutics include Skye Bioscience (SKYE), Allarity Therapeutics (ALLR), Marker Therapeutics (MRKR), NLS Pharmaceutics (NCEL), and Quantum Biopharma (QNTM). These companies are all part of the "biotechnology" industry.

How does Aptevo Therapeutics compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by insiders. Comparatively, 0.5% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Skye Bioscience has a beta of 2.97, meaning that its stock price is 197% more volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Skye Bioscience is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

In the previous week, Skye Bioscience had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Skye Bioscience and 1 mentions for Aptevo Therapeutics. Skye Bioscience's average media sentiment score of 0.37 beat Aptevo Therapeutics' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aptevo Therapeutics' return on equity of -198.50% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Skye Bioscience presently has a consensus price target of $8.50, indicating a potential upside of 1,491.76%. Given Skye Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Skye Bioscience is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Skye Bioscience beats Aptevo Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Allarity Therapeutics currently has a consensus target price of $10.25, suggesting a potential upside of 630.06%. Given Allarity Therapeutics' higher probable upside, equities research analysts plainly believe Allarity Therapeutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Allarity Therapeutics' return on equity of -109.94% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Allarity Therapeutics has higher revenue and earnings than Aptevo Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	69.81	-$11.23M	-$0.72	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by company insiders. Comparatively, 0.5% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Allarity Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

In the previous week, Aptevo Therapeutics had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 1 mentions for Aptevo Therapeutics and 0 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 0.00 equaled Aptevo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Allarity Therapeutics	Neutral
Aptevo Therapeutics	Neutral

Summary

Allarity Therapeutics beats Aptevo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Aptevo Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Marker Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 0.5% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aptevo Therapeutics had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for Aptevo Therapeutics and 0 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.00 equaled Aptevo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Marker Therapeutics	Neutral
Aptevo Therapeutics	Neutral

Marker Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 788.89%. Given Marker Therapeutics' higher probable upside, research analysts plainly believe Marker Therapeutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Marker Therapeutics has higher revenue and earnings than Aptevo Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	5.28	-$12.16M	-$0.61	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

Summary

Marker Therapeutics beats Aptevo Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aptevo Therapeutics compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

NLS Pharmaceutics currently has a consensus target price of $23.00, indicating a potential upside of 621.00%. Given NLS Pharmaceutics' higher probable upside, research analysts clearly believe NLS Pharmaceutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Aptevo Therapeutics had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for Aptevo Therapeutics and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Aptevo Therapeutics'average media sentiment score.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Aptevo Therapeutics	Neutral

8.1% of Aptevo Therapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by insiders. Comparatively, 0.5% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

NLS Pharmaceutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Aptevo Therapeutics	N/A	-198.50%	-117.06%

NLS Pharmaceutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

Summary

NLS Pharmaceutics beats Aptevo Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Quantum Biopharma had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Quantum Biopharma and 1 mentions for Aptevo Therapeutics. Quantum Biopharma's average media sentiment score of 1.05 beat Aptevo Therapeutics' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quantum Biopharma has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 0.5% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aptevo Therapeutics' return on equity of -198.50% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Quantum Biopharma is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

Summary

Aptevo Therapeutics beats Quantum Biopharma on 8 of the 12 factors compared between the two stocks.

Get Aptevo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APVO vs. The Competition

Export

Metric	Aptevo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.26M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.02	9.06	269.91	24.87
Price / Sales	N/A	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.24	17.97	11.40	6.45
Net Income	-$25.97M	-$13.25M	$3.45B	$347.50M
7 Day Performance	4.28%	5.58%	3.66%	3.77%
1 Month Performance	4.54%	-1.60%	-0.49%	-0.40%
1 Year Performance	-89.87%	61.32%	77.51%	23.55%

Aptevo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APVO Aptevo Therapeutics	0.6102 of 5 stars	$4.12 -1.4%	N/A	-89.7%	$6.26M	N/A	N/A	50	News Coverage
SKYE Skye Bioscience	2.0453 of 5 stars	$0.57 -2.0%	$8.50 +1,395.2%	-85.2%	$19.98M	N/A	N/A	11
ALLR Allarity Therapeutics	1.7241 of 5 stars	$1.21 -1.6%	$10.25 +747.1%	+43.3%	$19.25M	$320K	N/A	10
MRKR Marker Therapeutics	1.6902 of 5 stars	$1.13 +0.9%	$10.00 +785.0%	-5.9%	$18.84M	$3.55M	N/A	60	Upcoming Earnings Gap Up
NCEL NLS Pharmaceutics	1.8284 of 5 stars	$3.49 +3.9%	$23.00 +559.0%	-84.5%	$18.65M	N/A	N/A	6	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APVO) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptevo Therapeutics (APVO) Competitors

APVO vs. SKYE, ALLR, MRKR, NCEL, and QNTM

How does Aptevo Therapeutics compare to Skye Bioscience?

Summary

How does Aptevo Therapeutics compare to Allarity Therapeutics?

Summary

How does Aptevo Therapeutics compare to Marker Therapeutics?

Summary

How does Aptevo Therapeutics compare to NLS Pharmaceutics?

Summary

How does Aptevo Therapeutics compare to Quantum Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptevo Therapeutics (APVO) Competitors

APVO vs. SKYE, ALLR, MRKR, NCEL, and QNTM

How does Aptevo Therapeutics compare to Skye Bioscience?

Do institutionals & insiders believe in SKYE or APVO?

Which has more risk & volatility, SKYE or APVO?

Which has stronger valuation & earnings, SKYE or APVO?

Does the media prefer SKYE or APVO?

Is SKYE or APVO more profitable?

Do analysts prefer SKYE or APVO?

Summary

How does Aptevo Therapeutics compare to Allarity Therapeutics?

Do analysts prefer ALLR or APVO?

Is ALLR or APVO more profitable?

Which has better valuation & earnings, ALLR or APVO?

Do institutionals and insiders hold more shares of ALLR or APVO?

Which has more risk and volatility, ALLR or APVO?

Does the media prefer ALLR or APVO?

Summary

How does Aptevo Therapeutics compare to Marker Therapeutics?

Is MRKR or APVO more profitable?

Which has more risk & volatility, MRKR or APVO?

Do insiders & institutionals believe in MRKR or APVO?

Does the media favor MRKR or APVO?

Do analysts prefer MRKR or APVO?

Which has preferable earnings & valuation, MRKR or APVO?

Summary

How does Aptevo Therapeutics compare to NLS Pharmaceutics?

Do analysts rate NCEL or APVO?

Does the media prefer NCEL or APVO?

Do insiders and institutionals have more ownership in NCEL or APVO?

Which has preferable valuation and earnings, NCEL or APVO?

Is NCEL or APVO more profitable?

Which has more risk and volatility, NCEL or APVO?

Summary

How does Aptevo Therapeutics compare to Quantum Biopharma?

Do analysts prefer QNTM or APVO?

Does the media prefer QNTM or APVO?

Which has more risk and volatility, QNTM or APVO?

Do insiders and institutionals believe in QNTM or APVO?

Is QNTM or APVO more profitable?

Which has preferable earnings & valuation, QNTM or APVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools